Prevalence of Hyperuricemia and Its Association with Cardiovascular Risk Factors and Subclinical Target Organ Damage
Ver/ Abrir
Impacto
Scholar |
Otros documentos de la autoría: Antelo Pais, Paula; PRIETO-DIAZ, MIGUEL ANGEL; MICÓ PÉREZ, RAFAEL MANUEL; Pallarés-Carratalá, Vicente; Velilla-zancada, Sonsoles; Polo García, José Luis; barquilla garcía, alfonso; Ginel-Mendoza, Leovigildo; Segura Fragoso, Antonio; Vitelli-Storelli, Facundo; Martin, V.; Hermida-Ameijeiras, Alvaro; Cinza-Sanjurjo, Sergio
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Prevalence of Hyperuricemia and Its Association with Cardiovascular Risk Factors and Subclinical Target Organ DamageAutoría
Fecha de publicación
2022-12-21Editor
MDPIISSN
2077-0383Cita bibliográfica
Antelo-Pais, P.; Prieto-Díaz, M.Á.; Micó-Pérez, R.M.; PallarésCarratalá, V.; Velilla-Zancada, S.; Polo-García, J.; Barquilla-García, A.; Ginel-Mendoza, L.; Segura-Fragoso, A.; Vitelli-Storelli, F.; et al. Prevalence of Hyperuricemia and Its Association with Cardiovascular Risk Factors and Subclinical Target Organ Damage. J. Clin. Med. 2023, 12, 50. https:// doi.org/10.3390/jcm12010050Tipo de documento
info:eu-repo/semantics/articleVersión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
The role of uric acid levels in the cardiovascular continuum is not clear. Our objective is to
analyze the prevalence of hyperuricemia (HU) and its association with cardiovascular risk factors
(CVRF), subclinical ... [+]
The role of uric acid levels in the cardiovascular continuum is not clear. Our objective is to
analyze the prevalence of hyperuricemia (HU) and its association with cardiovascular risk factors
(CVRF), subclinical target organ damage (sTOD), and cardiovascular diseases (CVD). We evaluated
the prevalence of HU in 6.927 patients included in the baseline visit of the IBERICAN study. HU
was defined as uric acid levels above 6 mg/dL in women, and 7 mg/dL in men. Using adjusted
logistic regression models, the odds ratios were estimated according to CVRF, sTOD, and CVD. The
prevalence of HU was 16.3%. The risk of HU was higher in patients with pathological glomerular
filtration rate (aOR: 2.92), heart failure (HF) (aOR: 1.91), abdominal obesity (aOR: 1.80), hypertension
(HTN) (aOR: 1.65), use of thiazides (aOR: 1.54), left ventricular hypertrophy (LVH) (aOR: 1.36), atrial
fibrillation (AFIB) (aOR: 1.29), and albuminuria (aOR: 1.27). On the other hand, being female (aOR:
0.82) showed a reduced risk. The prevalence of HU was higher in men, in patients presenting CVRF
such as HTN and abdominal obesity, and with co-existence of LVH, atrial fibrillation (AFIB), HF, and
any form of kidney injury. These associations raise the possibility that HU forms part of the early
stages of the cardiovascular continuum. This may influence its management in Primary Healthcare
because the presence of HU could mean an increased CV risk in the patients. [-]
Publicado en
J. Clin. Med. 2023, 12, 50. https://doi.org/10.3390/jcm12010050Entidad financiadora
SEMERGEN Foundation
Derechos de acceso
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- MED_Articles [637]
Excepto si se señala otra cosa, la licencia del ítem se describe como: Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).